Blending of Designer Synthetic Polymers to a Dual Targeted Nanoformulation for SARS-CoV-2 Associated Kidney Damage

Abstract

As the COVID-19 pandemic has continued to spread, studies have shown that hospitalized COVID-19 patients are at significant risk for developing acute kidney injury (AKI), which can cause increased morbidity, the need for dialysis treatment, chronic kidney diseases, and even death. In this paper, we present a proof-of-concept study for the utilization of combination therapeutic-loaded dual-targeted biodegradable nanoparticles (NPs) to treat concurrent AKI and COVID-19 in patients by delivering the therapeutics across the gut epithelial barrier and to the kidney, in order to lower the viral load as well as reduce the symptoms of AKI. Despite recent vaccination efforts and the end of the COVID-19 pandemic in sight, problems related to the long-term effects of COVID-19 will continue to persist, including impacts on patients suffering from AKI and other chronic renal conditions. Therefore, the dual-targeted blended polymeric NP developed in this study to treat concurrent COVID-19 infection and AKI is a useful proof-of-concept nanoplatform for future treatments of these complications.

New Pathway for Cisplatin Prodrug to Utilize Metabolic Substrate Preference to Overcome Cancer Intrinsic Resistance

“…The data revealed that the expression of PSMA was significantly higher in the cancerous region of both non-ADT- and ADT-treated groups as compared to the respective benign regions (Figure A, B, Supporting Information Figures S25, S26). In order to target the PSMA expressing prostate cancer cells, we developed biodegradable orally administrable PSMA targeted nanoparticles from PLGA- b -PEG 3500 -GLU and PLGA- b -PEG 6000 -Mal polymers which were previously reported by us (Figure C). Using these polymers, Platin-L-loaded dual-targeted NPs (T-Fc-GLU-Platin-L-NPs) were synthesized via a nanoprecipitation technique using a ratio of 50:50 PLGA- b -PEG 3500 -GLU/PLGA- b -PEG 6000 -Mal and a 20% feed of Platin-L with respect to the total amount of polymer (Figure C).…”

Natural products applied in acute kidney injury treatment: polymer matters

“…It is an obscure way for orally administered nanoparticles or other prodrugs to go from the gut to kidneys, and that is why almost all the complexes reported were administered intravenously, but surprisingly, there have still been several attempts focusing on orally-delivered strategies for AKI therapy, which doubtlessly leads to high adherence of patients and more convenience for treatment. 94,107 Fig. 8 Illustrative scheme of an ultra-small nanodot based on phosphotungstic acid and tannic acid, and its mechanism of renal protection.…”

Nanoscale Technologies in the Fight against COVID-19: From Innovative Nanomaterials to Computer-Aided Discovery of Potential Antiviral Plant-Derived Drugs

“…Kidney and glomerular cells contain ACE2 receptors and are susceptible to SARS-CoV-2 virus entry and infection. Surnar et al [ 225 ] developed orally administrable, dual-targeted NPs to deliver the antiviral drug IVM, and the antioxidant supplement coenzyme Q10 (CoQ10), with the aim to treat SARS-CoV-2 infection and AKI related to COVID-19. These polymeric NPs are based on PLGA-b-poly(ethylene glycol)-maleimide (PLGA-b-PEG2000-Mal) conjugated with Fc (fragment crystallizable) and GLU (a glutamate–urea-based ligand).…”